In short
Clinical trials are studying ANGIOTENSIN II in different patient groups, including adults after cardiac surgery, people with liver cancer, and children with life-threatening low blood pressure. These studies look at safety and how well the treatment works in each setting.
Key points
- Clinical trials of ANGIOTENSIN II are studying three very different uses: preventing acute kidney injury after cardiac surgery, improving radioembolization for liver cancer, and helping children with life-threatening low blood pressure. The trials include adults and children, depending on the study. One trial is Phase 2, one is Phase 3, and one is listed as Low Intervention. The main outcomes focus on kidney injury rates, tumor treatment response, and changes in vasopressor dose. All three studies are marked Authorised.
Trial overview
The data include three interventional studies of ANGIOTENSIN II, each looking at a different clinical problem: kidney injury after heart surgery, liver cancer treatment, and severe low blood pressure in children.
All three studies are marked Authorised, which means they have been approved to move forward in the study process.
Acute kidney injury study after cardiac surgery
Trial NCT06615102 is studying whether ANGIOTENSIN II can reduce the occurrence of acute kidney injury after cardiac surgery. The trial compares ANGIOTENSIN II with norepinephrine, another blood pressure medicine, in people after heart surgery.
The main outcome is the rate of AKI KDIGO stage 2 or 3, or death, within 72 hours after surgery. KDIGO is a kidney injury staging system; stage 2 or 3 means a more serious level of kidney injury.
This study is large, with an enrollment of 1022 people, and it is listed as Low Intervention in the source data.
Liver cancer radioembolization study
Trial 2025-521870-33-00 is called the RADIANT study and is testing ANGIOTENSIN II in people with primary or secondary liver cancer. The study looks at whether ANGIOTENSIN II can make radioembolization more effective.
Radioembolization is a cancer treatment that delivers tiny radioactive microspheres into the blood supply of the tumor. In this study, the main measure is the tumor-to-non-tumor ratio, which compares how much treatment reaches the tumor versus nearby normal tissue.
The trial uses imaging tests called 90Y PET/CT and 99mTc-MAA SPECT/CT to compare results with and without ANGIOTENSIN II. It is a small Phase 2 study with 15 participants.
Pediatric shock and low blood pressure study
Trial 2025-523750-14-00 is studying ANGIOTENSIN II in patients 0 to 17 years old who have refractory hypotension in distributive shock. Refractory hypotension means blood pressure that stays too low even after usual treatment.
The study compares ANGIOTENSIN II with placebo while children receive fluids and standard-of-care vasopressors. A placebo is a treatment with no active medicine, used here to help compare results fairly.
The main outcome is the change in the dose of standard blood pressure medicines, measured as norepinephrine base equivalent dose, during the first 6 hours of treatment. This Phase 3 trial includes 143 participants.
Main outcomes and what they mean
The kidney study focuses on whether serious kidney injury or death happens within 72 hours after cardiac surgery.
The liver cancer study focuses on whether ANGIOTENSIN II improves the tumor-to-non-tumor ratio after treatment, which may show better targeting of the tumor area.
The pediatric shock study focuses on whether ANGIOTENSIN II can reduce the amount of standard blood pressure medicine needed in the first 6 hours.
Who the trials are for
These studies are not for one single disease group; they are designed for very different patients.
- The first study is for people after cardiac surgery who are at risk of acute kidney injury.
- The second study is for people with primary or secondary liver cancer.
- The third study is for children and teenagers from 0 to 17 years old with refractory hypotension in distributive shock.
Study phases and current status
The source data show one Phase 2 study, one Phase 3 study, and one study labeled Low Intervention.
Phase 2 studies usually look more closely at whether a treatment seems to work and how it performs in a smaller group, while Phase 3 studies compare treatments in larger groups to confirm results.
All three studies are marked Authorised, and their enrollment ranges from 15 to 1022 participants.